Full text is available at the source.
Abstract
Essence
Three cases raise a hypothesis that GLP-1 agonists could trigger or worsen type 1 autoimmune pancreatitis in susceptible patients.
Evidence
Case series reports three type 1 autoimmune pancreatitis cases following GLP-1 agonist treatment for type 2 diabetes and discusses possible pancreatic hypertrophy and antigen-presentation mechanisms.
Caveat
Causation remains unproven because the report has only three cases, no comparator group, and a mechanistic hypothesis rather than direct proof.
Simplified
GLP-1 Therapies